Cargando…

A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma

BACKGROUND: This pilot study was designed to evaluate the diagnostic value of (68) Ga-PSMA-617 and (18)F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. METHODS: Thirty patients pathologically diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guochang, Zhou, Mengjiao, Zang, Jie, Jiang, Yuanyuan, Chen, Xiaohong, Zhu, Zhaohui, Chen, Xiaoyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390098/
https://www.ncbi.nlm.nih.gov/pubmed/35984529
http://dx.doi.org/10.1186/s13550-022-00922-x
_version_ 1784770576676552704
author Wang, Guochang
Zhou, Mengjiao
Zang, Jie
Jiang, Yuanyuan
Chen, Xiaohong
Zhu, Zhaohui
Chen, Xiaoyuan
author_facet Wang, Guochang
Zhou, Mengjiao
Zang, Jie
Jiang, Yuanyuan
Chen, Xiaohong
Zhu, Zhaohui
Chen, Xiaoyuan
author_sort Wang, Guochang
collection PubMed
description BACKGROUND: This pilot study was designed to evaluate the diagnostic value of (68) Ga-PSMA-617 and (18)F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. METHODS: Thirty patients pathologically diagnosed with ACC were recruited into the cohort. Each patient underwent (68) Ga-PSMA-617 and (18)F-FDG PET/CT within 1 week. The number and SUVmax of PET-positive lesions were recorded and compared. Four patients accepted RLT using (177)Lu-EB-PSMA-617, in a dosage of approximately 1.85 GBq (50 mCi) per cycle for up to 3 cycles. RESULTS: Compared with (18)F-FDG, (68) Ga-PSMA-617 revealed more PET-positive extrapulmonary tumors (157 vs. 141, P = 0.016) and higher SUVmax (8.8 ± 3.6 vs. 6.4 ± 4.2, P = 0.027). However, (68) Ga-PSMA-617 revealed less PET-positive pulmonary lesions (202 vs. 301, P < 0.001) and lower SUVmax of tumors (3.1 ± 3.0 vs. 4.2 ± 3.9, P < 0.001) than (18)F-FDG. The combination of (68) Ga-PSMA-617 and (18)F-FDG can detect 469 PET-positive lesions, which was superior to each alone (469 vs. 359 vs. 442, P < 0.001). Two patients achieved remarkable response after PSMA RLT, while the other two patients showed reduced tumor uptake of recurrent foci, lung and liver metastases, whereas increased SUVmax of bone metastases. CONCLUSIONS: (68) Ga-PSMA-617 PET/CT is a valuable imaging modality for the detection of ACC and combining with (18)F-FDG PET/CT will achieve a higher detection efficiency. PSMA RLT may be a promising treatment for ACC and is worth of further investigation. Trial registration: Diagnosis of Adenoid Cystic Carcinoma on (68) Ga-PSMA-617 PET-CT and Therapy With (177)Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL of registry: https://clinicaltrials.gov/ct2/show/NCT04801264.
format Online
Article
Text
id pubmed-9390098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93900982022-08-21 A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma Wang, Guochang Zhou, Mengjiao Zang, Jie Jiang, Yuanyuan Chen, Xiaohong Zhu, Zhaohui Chen, Xiaoyuan EJNMMI Res Original Research BACKGROUND: This pilot study was designed to evaluate the diagnostic value of (68) Ga-PSMA-617 and (18)F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients. METHODS: Thirty patients pathologically diagnosed with ACC were recruited into the cohort. Each patient underwent (68) Ga-PSMA-617 and (18)F-FDG PET/CT within 1 week. The number and SUVmax of PET-positive lesions were recorded and compared. Four patients accepted RLT using (177)Lu-EB-PSMA-617, in a dosage of approximately 1.85 GBq (50 mCi) per cycle for up to 3 cycles. RESULTS: Compared with (18)F-FDG, (68) Ga-PSMA-617 revealed more PET-positive extrapulmonary tumors (157 vs. 141, P = 0.016) and higher SUVmax (8.8 ± 3.6 vs. 6.4 ± 4.2, P = 0.027). However, (68) Ga-PSMA-617 revealed less PET-positive pulmonary lesions (202 vs. 301, P < 0.001) and lower SUVmax of tumors (3.1 ± 3.0 vs. 4.2 ± 3.9, P < 0.001) than (18)F-FDG. The combination of (68) Ga-PSMA-617 and (18)F-FDG can detect 469 PET-positive lesions, which was superior to each alone (469 vs. 359 vs. 442, P < 0.001). Two patients achieved remarkable response after PSMA RLT, while the other two patients showed reduced tumor uptake of recurrent foci, lung and liver metastases, whereas increased SUVmax of bone metastases. CONCLUSIONS: (68) Ga-PSMA-617 PET/CT is a valuable imaging modality for the detection of ACC and combining with (18)F-FDG PET/CT will achieve a higher detection efficiency. PSMA RLT may be a promising treatment for ACC and is worth of further investigation. Trial registration: Diagnosis of Adenoid Cystic Carcinoma on (68) Ga-PSMA-617 PET-CT and Therapy With (177)Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL of registry: https://clinicaltrials.gov/ct2/show/NCT04801264. Springer Berlin Heidelberg 2022-08-19 /pmc/articles/PMC9390098/ /pubmed/35984529 http://dx.doi.org/10.1186/s13550-022-00922-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Wang, Guochang
Zhou, Mengjiao
Zang, Jie
Jiang, Yuanyuan
Chen, Xiaohong
Zhu, Zhaohui
Chen, Xiaoyuan
A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
title A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
title_full A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
title_fullStr A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
title_full_unstemmed A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
title_short A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
title_sort pilot study of (68) ga-psma-617 pet/ct imaging and (177)lu-eb-psma-617 radioligand therapy in patients with adenoid cystic carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390098/
https://www.ncbi.nlm.nih.gov/pubmed/35984529
http://dx.doi.org/10.1186/s13550-022-00922-x
work_keys_str_mv AT wangguochang apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT zhoumengjiao apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT zangjie apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT jiangyuanyuan apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT chenxiaohong apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT zhuzhaohui apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT chenxiaoyuan apilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT wangguochang pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT zhoumengjiao pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT zangjie pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT jiangyuanyuan pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT chenxiaohong pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT zhuzhaohui pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma
AT chenxiaoyuan pilotstudyof68gapsma617petctimagingand177luebpsma617radioligandtherapyinpatientswithadenoidcysticcarcinoma